Physician profile
Brian Jay Kaplan
NPI 1164505236
$10,570.29
in general payments reported to CMS, 2019-2025
13 companies · $7,198 in 2025
The $7,198 reported for 2025 was more than what 91% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $108 · 2022: $121 · 2023: $1,040 · 2024: $1,118 · 2025: $7,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,472 · Food and Beverage: $1,656 · Travel and Lodging: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,472.28 |
| Food and Beverage | $1,655.57 |
| Travel and Lodging | $1,228.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,039.74 | 2025 | |
| Medtronic, INC. | $1,093.47 | 2022-2024 | Signia |
| Conmed Corporation | $800.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $655.99 | 2023-2025 | Menopur, Endometrin, Rebyota |
| Abbvie INC. | $230.31 | 2024-2025 | |
| Silk Road Medical, INC. | $221.31 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Baxter Healthcare | $148.21 | 2024 | |
| Covidien LP | $107.80 | 2020 | |
| Tactile Systems Technology INC | $91.15 | 2019 | |
| Civatech Oncology, INC. | $78.40 | 2019 | |
| Ethicon US, LLC | $66.26 | 2023-2024 | Echelon Endopath, Evarrest |
| Alcresta Therapeutics, INC. | $22.70 | 2024 | Relizorb |
| Medtronic Vascular, INC. | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.